APO Research
Talk to an analyst

APO RESEARCH · REPORT

Active Tuberculosis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Active Tuberculosis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchActive Tuberculosis Treatment Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Active Tuberculosis Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Active Tuberculosis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Active Tuberculosis Treatment Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Active Tuberculosis Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Active Tuberculosis Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Active Tuberculosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Active Tuberculosis Treatment include Teva Pharmaceutical Industries Ltd., Sanofi, Johnson & Johnson, Novartis AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Macleods Pharmaceuticals Ltd., Lupin and KGaA (Fresenius Kabi), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Active Tuberculosis Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Active Tuberculosis Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Active Tuberculosis Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Active Tuberculosis Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Active Tuberculosis Treatment Segment by Company

Teva Pharmaceutical Industries Ltd.

Sanofi

Johnson & Johnson

Novartis AG

Pfizer Inc.

Otsuka Pharmaceutical Co., Ltd.

Macleods Pharmaceuticals Ltd.

Lupin

KGaA (Fresenius Kabi)

FRESENIUS SE & Co

ANI Pharmaceuticals, Inc.

Active Tuberculosis Treatment Segment by Type

Ethambutol

Rifampin

Pyrazinamide

Active Tuberculosis Treatment Segment by Application

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Pharmacies

Active Tuberculosis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Active Tuberculosis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Active Tuberculosis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Active Tuberculosis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Active Tuberculosis Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Active Tuberculosis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Active Tuberculosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Active Tuberculosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Active Tuberculosis Treatment Industry Trends Table 2. Active Tuberculosis Treatment Industry Drivers Table 3. Active Tuberculosis Treatment Industry Opportunities and Challenges Table 4. Active Tuberculosis Treatment Industry Restraints Table 5. Global Active Tuberculosis Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Active Tuberculosis Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Active Tuberculosis Treatment Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Active Tuberculosis Treatment Sales Market Share by Manufacturers Table 9. Global Active Tuberculosis Treatment Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Active Tuberculosis Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Active Tuberculosis Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Active Tuberculosis Treatment Manufacturers, Product Type & Application Table 13. Global Active Tuberculosis Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Active Tuberculosis Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ethambutol Table 17. Major Manufacturers of Rifampin Table 18. Major Manufacturers of Pyrazinamide Table 19. Global Active Tuberculosis Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Active Tuberculosis Treatment Sales by Type (2021-2026) & (k units) Table 21. Global Active Tuberculosis Treatment Sales by Type (2027-2032) & (k units) Table 22. Global Active Tuberculosis Treatment Sales Market Share by Type (2021-2026) Table 23. Global Active Tuberculosis Treatment Sales Market Share by Type (2027-2032) Table 24. Global Active Tuberculosis Treatment Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Active Tuberculosis Treatment Revenue by Type (2021-2026) & (k units) Table 26. Global Active Tuberculosis Treatment Revenue by Type (2027-2032) & (k units) Table 27. Global Active Tuberculosis Treatment Revenue Market Share by Type (2021-2026) Table 28. Global Active Tuberculosis Treatment Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Pharmacies Table 30. Major Manufacturers of Drug Stores and Retail Pharmacies Table 31. Major Manufacturers of Online Pharmacies Table 32. Global Active Tuberculosis Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Active Tuberculosis Treatment Sales by Application (2021-2026) & (k units) Table 34. Global Active Tuberculosis Treatment Sales by Application (2027-2032) & (k units) Table 35. Global Active Tuberculosis Treatment Sales Market Share by Application (2021-2026) Table 36. Global Active Tuberculosis Treatment Sales Market Share by Application (2027-2032) Table 37. Global Active Tuberculosis Treatment Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Active Tuberculosis Treatment Revenue by Application (2021-2026) & (k units) Table 39. Global Active Tuberculosis Treatment Revenue by Application (2027-2032) & (k units) Table 40. Global Active Tuberculosis Treatment Revenue Market Share by Application (2021-2026) Table 41. Global Active Tuberculosis Treatment Revenue Market Share by Application (2027-2032) Table 42. Global Active Tuberculosis Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Active Tuberculosis Treatment Sales by Region (2021-2026) & (k units) Table 44. Global Active Tuberculosis Treatment Sales Market Share by Region (2021-2026) Table 45. Global Active Tuberculosis Treatment Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Active Tuberculosis Treatment Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 49. North America Active Tuberculosis Treatment Sales by Country (2027-2032) & (k units) Table 50. Europe Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 52. Europe Active Tuberculosis Treatment Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Active Tuberculosis Treatment Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Active Tuberculosis Treatment Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Active Tuberculosis Treatment Sales by Country (2027-2032) & (k units) Table 59. Global Active Tuberculosis Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Active Tuberculosis Treatment Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Active Tuberculosis Treatment Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Active Tuberculosis Treatment Revenue Market Share by Region (2021-2026) Table 63. Global Active Tuberculosis Treatment Revenue Market Share by Region (2027-2032) Table 64. Teva Pharmaceutical Industries Ltd. Company Information Table 65. Teva Pharmaceutical Industries Ltd. Business Overview Table 66. Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Product Portfolio Table 68. Teva Pharmaceutical Industries Ltd. Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Active Tuberculosis Treatment Product Portfolio Table 73. Sanofi Recent Development Table 74. Johnson & Johnson Company Information Table 75. Johnson & Johnson Business Overview Table 76. Johnson & Johnson Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Johnson & Johnson Active Tuberculosis Treatment Product Portfolio Table 78. Johnson & Johnson Recent Development Table 79. Novartis AG Company Information Table 80. Novartis AG Business Overview Table 81. Novartis AG Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Novartis AG Active Tuberculosis Treatment Product Portfolio Table 83. Novartis AG Recent Development Table 84. Pfizer Inc. Company Information Table 85. Pfizer Inc. Business Overview Table 86. Pfizer Inc. Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pfizer Inc. Active Tuberculosis Treatment Product Portfolio Table 88. Pfizer Inc. Recent Development Table 89. Otsuka Pharmaceutical Co., Ltd. Company Information Table 90. Otsuka Pharmaceutical Co., Ltd. Business Overview Table 91. Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Product Portfolio Table 93. Otsuka Pharmaceutical Co., Ltd. Recent Development Table 94. Macleods Pharmaceuticals Ltd. Company Information Table 95. Macleods Pharmaceuticals Ltd. Business Overview Table 96. Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Product Portfolio Table 98. Macleods Pharmaceuticals Ltd. Recent Development Table 99. Lupin Company Information Table 100. Lupin Business Overview Table 101. Lupin Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Lupin Active Tuberculosis Treatment Product Portfolio Table 103. Lupin Recent Development Table 104. KGaA (Fresenius Kabi) Company Information Table 105. KGaA (Fresenius Kabi) Business Overview Table 106. KGaA (Fresenius Kabi) Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. KGaA (Fresenius Kabi) Active Tuberculosis Treatment Product Portfolio Table 108. KGaA (Fresenius Kabi) Recent Development Table 109. FRESENIUS SE & Co Company Information Table 110. FRESENIUS SE & Co Business Overview Table 111. FRESENIUS SE & Co Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. FRESENIUS SE & Co Active Tuberculosis Treatment Product Portfolio Table 113. FRESENIUS SE & Co Recent Development Table 114. ANI Pharmaceuticals, Inc. Company Information Table 115. ANI Pharmaceuticals, Inc. Business Overview Table 116. ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Product Portfolio Table 118. ANI Pharmaceuticals, Inc. Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Active Tuberculosis Treatment Distributors List Table 122. Active Tuberculosis Treatment Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Active Tuberculosis Treatment Product Image Figure 2. Global Active Tuberculosis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Active Tuberculosis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Active Tuberculosis Treatment Sales (2021-2032) & (k units) Figure 5. Global Active Tuberculosis Treatment Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Active Tuberculosis Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ethambutol Image Figure 9. Rifampin Image Figure 10. Pyrazinamide Image Figure 11. Global Active Tuberculosis Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Active Tuberculosis Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Active Tuberculosis Treatment Sales Market Share by Type (2021-2032) Figure 14. Global Active Tuberculosis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Active Tuberculosis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Active Tuberculosis Treatment Revenue Market Share by Type (2021-2032) Figure 17. Hospital Pharmacies Image Figure 18. Drug Stores and Retail Pharmacies Image Figure 19. Online Pharmacies Image Figure 20. Global Active Tuberculosis Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Active Tuberculosis Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Active Tuberculosis Treatment Sales Market Share by Application (2021-2032) Figure 23. Global Active Tuberculosis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Active Tuberculosis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Active Tuberculosis Treatment Revenue Market Share by Application (2021-2032) Figure 26. North America Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Active Tuberculosis Treatment Sales Market Share by Country (2021-2032) Figure 28. U.S. Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Active Tuberculosis Treatment Sales Market Share by Country (2021-2032) Figure 33. Germany Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Active Tuberculosis Treatment Sales Market Share by Country (2021-2032) Figure 40. China Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Active Tuberculosis Treatment Sales Market Share by Country (2021-2032) Figure 48. Brazil Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Active Tuberculosis Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Active Tuberculosis Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Active Tuberculosis Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Active Tuberculosis Treatment Revenue (2021-2032) & (US$ Million) Figure 59. North America Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Active Tuberculosis Treatment Revenue (2021-2032) & (US$ Million) Figure 61. Europe Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Active Tuberculosis Treatment Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Active Tuberculosis Treatment Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Active Tuberculosis Treatment Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Active Tuberculosis Treatment Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Ethambutol
  • Rifampin
  • Pyrazinamide
Applications
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Lupin
  • KGaA (Fresenius Kabi)
  • FRESENIUS SE & Co
  • ANI Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Active Tuberculosis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Active Tuberculosis Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Active Tuberculosis Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Active Tuberculosis Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Active Tuberculosis Treatment Market Dynamics
  1. 2.1 Active Tuberculosis Treatment Industry Trends
  2. 2.2 Active Tuberculosis Treatment Industry Drivers
  3. 2.3 Active Tuberculosis Treatment Industry Opportunities and Challenges
  4. 2.4 Active Tuberculosis Treatment Industry Restraints
3 Active Tuberculosis Treatment Market by Manufacturers
  1. 3.1 Global Active Tuberculosis Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Active Tuberculosis Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Active Tuberculosis Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Active Tuberculosis Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Active Tuberculosis Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Active Tuberculosis Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Active Tuberculosis Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Active Tuberculosis Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Active Tuberculosis Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Active Tuberculosis Treatment Tier 1, Tier 2, and Tier 3
4 Active Tuberculosis Treatment Market by Type
  1. 4.1 Active Tuberculosis Treatment Type Introduction
  2. 4.1.1 Ethambutol
  3. 4.1.2 Rifampin
  4. 4.1.3 Pyrazinamide
  5. 4.2 Global Active Tuberculosis Treatment Sales by Type
  6. 4.2.1 Global Active Tuberculosis Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Active Tuberculosis Treatment Sales by Type (2021-2032)
  8. 4.2.3 Global Active Tuberculosis Treatment Sales Market Share by Type (2021-2032)
  9. 4.3 Global Active Tuberculosis Treatment Revenue by Type
  10. 4.3.1 Global Active Tuberculosis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Active Tuberculosis Treatment Revenue by Type (2021-2032)
  12. 4.3.3 Global Active Tuberculosis Treatment Revenue Market Share by Type (2021-2032)
5 Active Tuberculosis Treatment Market by Application
  1. 5.1 Active Tuberculosis Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores and Retail Pharmacies
  4. 5.1.3 Online Pharmacies
  5. 5.2 Global Active Tuberculosis Treatment Sales by Application
  6. 5.2.1 Global Active Tuberculosis Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Active Tuberculosis Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Active Tuberculosis Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Active Tuberculosis Treatment Revenue by Application
  10. 5.3.1 Global Active Tuberculosis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Active Tuberculosis Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Active Tuberculosis Treatment Revenue Market Share by Application (2021-2032)
6 Global Active Tuberculosis Treatment Sales by Region
  1. 6.1 Global Active Tuberculosis Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Active Tuberculosis Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Active Tuberculosis Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Active Tuberculosis Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Active Tuberculosis Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Active Tuberculosis Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Active Tuberculosis Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Active Tuberculosis Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Active Tuberculosis Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Active Tuberculosis Treatment Revenue by Region
  1. 7.1 Global Active Tuberculosis Treatment Revenue by Region
  2. 7.1.1 Global Active Tuberculosis Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Active Tuberculosis Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Active Tuberculosis Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Active Tuberculosis Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Active Tuberculosis Treatment Revenue (2021-2032)
  8. 7.2.2 North America Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Active Tuberculosis Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Active Tuberculosis Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Active Tuberculosis Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Active Tuberculosis Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd.
  2. 8.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Active Tuberculosis Treatment Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Active Tuberculosis Treatment Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Active Tuberculosis Treatment Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Pfizer Inc.
  26. 8.5.1 Pfizer Inc. Company Information
  27. 8.5.2 Pfizer Inc. Business Overview
  28. 8.5.3 Pfizer Inc. Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. Active Tuberculosis Treatment Product Portfolio
  30. 8.5.5 Pfizer Inc. Recent Developments
  31. 8.6 Otsuka Pharmaceutical Co., Ltd.
  32. 8.6.1 Otsuka Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Product Portfolio
  36. 8.6.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Macleods Pharmaceuticals Ltd.
  38. 8.7.1 Macleods Pharmaceuticals Ltd. Company Information
  39. 8.7.2 Macleods Pharmaceuticals Ltd. Business Overview
  40. 8.7.3 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Product Portfolio
  42. 8.7.5 Macleods Pharmaceuticals Ltd. Recent Developments
  43. 8.8 Lupin
  44. 8.8.1 Lupin Company Information
  45. 8.8.2 Lupin Business Overview
  46. 8.8.3 Lupin Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lupin Active Tuberculosis Treatment Product Portfolio
  48. 8.8.5 Lupin Recent Developments
  49. 8.9 KGaA (Fresenius Kabi)
  50. 8.9.1 KGaA (Fresenius Kabi) Company Information
  51. 8.9.2 KGaA (Fresenius Kabi) Business Overview
  52. 8.9.3 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Product Portfolio
  54. 8.9.5 KGaA (Fresenius Kabi) Recent Developments
  55. 8.10 FRESENIUS SE & Co
  56. 8.10.1 FRESENIUS SE & Co Company Information
  57. 8.10.2 FRESENIUS SE & Co Business Overview
  58. 8.10.3 FRESENIUS SE & Co Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 FRESENIUS SE & Co Active Tuberculosis Treatment Product Portfolio
  60. 8.10.5 FRESENIUS SE & Co Recent Developments
  61. 8.11 ANI Pharmaceuticals, Inc.
  62. 8.11.1 ANI Pharmaceuticals, Inc. Company Information
  63. 8.11.2 ANI Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Product Portfolio
  66. 8.11.5 ANI Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Active Tuberculosis Treatment Value Chain Analysis
  2. 9.1.1 Active Tuberculosis Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Active Tuberculosis Treatment Production Mode & Process
  6. 9.2 Active Tuberculosis Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Active Tuberculosis Treatment Distributors
  9. 9.2.3 Active Tuberculosis Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst